Heron Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRTX research report →
About the company
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents.
- CEO
- Craig Alexander Collard
- IPO
- 1987
- Employees
- 122
- HQ
- Cary, CA, US
Price Chart
- Market Cap
- $69.24M
- P/E
- -2.47
- P/S
- 0.46
- P/B
- 9.10
- EV/EBITDA
- -7.66
- Div Yield
- 0.00%
- Gross Margin
- 71.12%
- Op Margin
- -6.94%
- Net Margin
- -20.53%
- ROE
- -1115.29%
- ROIC
- -6.72%
- Revenue
- $154.90M · 7.36%
- Net Income
- $-20,195,000 · -48.71%
- EPS
- $-0.12 · -34.68%
- Op Income
- $-2,538,000
- FCF YoY
- -15.16%
- 52W High
- $2.28
- 52W Low
- $0.38
- 50D MA
- $0.76
- 200D MA
- $1.07
- Beta
- 1.57
- Avg Volume
- 3.22M
Get TickerSpark's AI analysis on HRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Duarte Ira | other | 12,500 |
| Jun 16, 26 | Duarte Ira | other | 3,555 |
| Jun 16, 26 | Duarte Ira | other | 12,500 |
| Jun 6, 26 | Forbes William P | other | 12,500 |
| Jun 6, 26 | Forbes William P | other | 12,500 |
| May 6, 26 | Hensley Mark Earl | other | 125,000 |
| May 6, 26 | Hensley Mark Earl | other | 125,000 |
| Apr 30, 26 | Hensley Mark Earl | other | 11,770 |
| Apr 30, 26 | Hensley Mark Earl | other | 11,770 |
| Apr 30, 26 | Forbes William P | other | 11,770 |
Our HRTX coverage
Recent articles, reports, and earnings notes.
No research on HRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HRTX report →Similar companies
Peers in the same neighborhood.